Compass Therapeutics, Inc. financial data

Symbol
CMPX on Nasdaq
Location
80 Guest Street, Boston, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.17K % -50.7%
Debt-to-equity 15.1 % +173%
Return On Equity -48.9 % -51%
Return On Assets -42.5 % -38.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 178M shares +29.3%
Common Stock, Shares, Outstanding 178M shares +29.1%
Entity Public Float 98M USD -65.4%
Common Stock, Value, Issued 53K USD +279%
Weighted Average Number of Shares Outstanding, Basic 169M shares +22.7%
Weighted Average Number of Shares Outstanding, Diluted 138M shares

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 55.3M USD +48.9%
General and Administrative Expense 16.1M USD +10.5%
Operating Income (Loss) -71.4M USD -28.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -16.6M USD -54.2%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -65.8M USD -37.8%
Earnings Per Share, Basic 0 USD/shares -22.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 46.2M USD +138%
Marketable Securities, Current 174M USD +76.1%
Cash, Cash Equivalents, and Short-term Investments 175M USD
Assets, Current 221M USD +56.7%
Property, Plant and Equipment, Net 119K USD -75.9%
Operating Lease, Right-of-Use Asset 9.45M USD +36%
Other Assets, Noncurrent 568K USD +77.5%
Assets 231M USD +55.1%
Accounts Payable, Current 3.1M USD +222%
Accrued Liabilities, Current 8.68M USD +198%
Liabilities, Current 12.4M USD +180%
Operating Lease, Liability, Noncurrent 9.23M USD +46.1%
Liabilities 21.6M USD +101%
Accumulated Other Comprehensive Income (Loss), Net of Tax 274K USD -43.6%
Retained Earnings (Accumulated Deficit) -415M USD -18.8%
Stockholders' Equity Attributable to Parent 210M USD +51.5%
Liabilities and Equity 231M USD +55.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13.2M USD +4.9%
Net Cash Provided by (Used in) Financing Activities -815K USD -105%
Net Cash Provided by (Used in) Investing Activities 11.6M USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 178M shares +29.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.44M USD -340%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 46.8M USD +141%
Deferred Tax Assets, Gross 61.4M USD +38.7%
Operating Lease, Liability 9.87M USD +43.5%
Depreciation 100K USD -50%
Payments to Acquire Property, Plant, and Equipment 18K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -66M USD -40.9%
Lessee, Operating Lease, Liability, to be Paid 11.8M USD +37.9%
Property, Plant and Equipment, Gross 6.74M USD -6.52%
Operating Lease, Liability, Current 633K USD +13.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.2M USD +117%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.59M USD +117%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.95M USD +15.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.25M USD +59.3%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.29M USD +59.2%
Operating Lease, Payments 1.3M USD 0%
Deferred Tax Assets, Net of Valuation Allowance 1.9M USD +291%
Share-based Payment Arrangement, Expense 8.78M USD +10.8%